Sinew Pharma (6634) announced that the research results on its SNP-6 series, a new metabolic dysfunction-associated steatohepatitis (MASH) drug under development, have been selected for presentation at the 2025 International Pharmaceutical Federation (FIP) World Congress. The company will officially disclose the latest progress in preclinical and phase II clinical trials in Copenhagen, Denmark on September 1.

Founded in 1912, FIP is a leading global organization for pharmacy and pharmaceutical research, with professional members and partners around the world. Its annual World Congress is one of the most influential international conferences in the field of pharmacy, attracting thousands of experts and scholars.

Sinew's SNP-6: A Multi-Target Drug with Broad Potential

Sinew Pharma stated that the SNP-6 series is a "first-in-class" drug with multiple mechanisms of action, demonstrating exceptional efficacy against MASH. The drug not only significantly inhibits triglyceride production, improves lipid metabolism pathways, and reduces the production of hepatotoxic metabolites, but also has the potential to be applied to the prevention and treatment of liver fibrosis. Its efficacy covers both alcoholic and non-alcoholic fatty liver diseases, giving it an advantage over other drugs in development that only target non-alcoholic fatty liver disease.

According to the latest phase II clinical trial results, SNP-6 successfully met its primary and secondary efficacy endpoints, indicating its strong potential in the treatment of MASH. Sinew Pharma has completed its global patent strategy, covering Taiwan, China, the United States, the European Union, the Eurasian Union, Canada, South Africa, India, Japan, and South Korea, demonstrating its ambition to become an international biotechnology new drug company.

A Much-Needed Solution for MASH

Although two MASH therapeutics have been approved by the U.S. FDA, including Resmetirom, the efficacy of existing single-targeted therapies is still limited due to the complex pathogenesis of MASH. Studies have shown that even with FDA-approved drugs, the rate of liver pathological improvement does not exceed 32%. Therefore, innovative drugs with multi-target or combination therapies have become an urgent need in the market, and the SNP-6 series of drugs address this need by four key mechanisms of action:

• Regulate liver fat metabolism: Effectively inhibits the absorption of fatty acids, reduces triglyceride synthesis, and reduces liver fat accumulation.
• Reduced oxidative stress: Significantly reduces the production of reactive oxygen species (ROS), mitigating oxidative damage to liver cells and related inflammatory responses.
• Anti-inflammatory and anti-fibrosis effects: Inhibits the release of pro-inflammatory and pro-fibrotic factors from liver and immune cells to slow down disease progression.
• Immunomodulation: Maintain the integrity of the intestinal barrier, reduce blood lipopolysaccharide (LPS), which in turn reduces liver inflammation and immune cell infiltration.

According to the journal “Drug Design, Development and Therapy,” MASH is the most common chronic liver disease in the world, affecting more than 35 million people. Future Market Insights forecasts the global market to exceed U.S. $51.4 billion by 2033, representing a compound annual growth rate of 33.3%.

Sinew Pharma's SNP-6 new drug series is poised to become a significant presence in the global pharmaceutical market, offering new hope in the fight against MASH.

Source after English translation